Doggrell Biomedical Communications, Wynnum, Australia.
Expert Opin Pharmacother. 2022 Mar;23(4):447-451. doi: 10.1080/14656566.2021.2019707. Epub 2021 Dec 29.
Obesity is a major risk factor for cardiovascular disease, diabetes, osteoarthritis, and some cancers. Weight loss is an obvious management for this, but a major problem is that after weight loss, many people regain weight.
In the following evaluation of S-LITE (NCT04122716, Combined effects of GLP-1 analogue and exercise on maintenance of weight loss after very-low calorie diet), the author gives emphasis to the prevention of weight regain by liraglutide, not the effects of exercise. In S-LITE, liraglutide (with or without exercise) was effective in reducing weight regain in subjects with obesity.
The subjects with obesity in S-LITE were limited by the enrollment criteria, and the findings of S-LITE cannot be generalized. The increased heart rate with liraglutide did not occur when liraglutide was combined with exercise, and this suggests that liraglutide should probably not be used alone, but only with exercise to maintain weight loss. As the only presently available medicine to have been shown to be effective against weight regain, liraglutide should probably be preferred to other weight-loss medicines in this circumstance. However, without clear evidence that liraglutide treatment for obesity prevents diabetes and/or reduces cardiovascular risk, it is difficult to justify using it.
肥胖是心血管疾病、糖尿病、骨关节炎和某些癌症的主要危险因素。减轻体重显然是一种治疗方法，但一个主要问题是，在体重减轻后，许多人会体重反弹。
在对 S-LITE（NCT04122716，GLP-1 类似物和运动对极低热量饮食后体重减轻的维持作用）的评估中，作者强调了利拉鲁肽预防体重反弹的作用，而不是运动的作用。在 S-LITE 中，利拉鲁肽（无论是否运动）在肥胖受试者中有效减少了体重反弹。
S-LITE 中的肥胖受试者受到入组标准的限制，因此 S-LITE 的研究结果不能推广。当利拉鲁肽与运动结合使用时，不会出现利拉鲁肽引起的心率增加，这表明利拉鲁肽可能不应该单独使用，而应该与运动结合使用以维持体重减轻。作为目前唯一被证明对体重反弹有效的药物，在这种情况下，利拉鲁肽可能优于其他减肥药物。然而，由于没有明确的证据表明利拉鲁肽治疗肥胖症可以预防糖尿病和/或降低心血管风险，因此很难证明使用它是合理的。
